- Associated Press - Friday, August 7, 2015

GAITHERSBURG, Md. (AP) - A biotechnology company has announced that it plans to split its research and manufacturing businesses into two companies.

The Baltimore Sun reports (https://bsun.md/1hnCObT ) Emergent BioSolutions made the announcement Thursday. Company officials say Emergent will maintain its production facility in Baltimore.

The Gaithersburg-based Emergent is looking to spin-off the research business into a stand-alone public company, which will work to develop treatments for cancer and blood diseases.

The move will help Emergent to increase profit as company leaders look to expand their growth in biodefense and preparedness for emerging infectious diseases.

CEO Daniel J. Abdun-Nabi says they expect the proposed spin-off to enhance business focus and unlock significant value for both companies.

Emergent has two facilities in Baltimore, among five sites where it develops and produces biodefense agents and other products.

Sign up for Daily Newsletters

Manage Newsletters

Copyright © 2021 The Washington Times, LLC.

Please read our comment policy before commenting.


Click to Read More and View Comments

Click to Hide